Given the recent advances in the mechanistic understanding of respiratory diseases, discovery of disease biomarkers and the introduction of a number of targeted add-on therapies for severe refractory asthma, both licensed and in development; there is a need for guidance for the treating clinician on whom, when and how they should treat patients, including recommendations around the appropriate selection and/or switching of targeted therapies in these patients.  The main aim of the research seminar is to gather a limited number of well-established experts, and interested members of the asthma community, to provide an opportunity to break new ground and address in-depth questions around the management challenges of patients with severe corticosteroid-refractory asthma.